Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670561 | 0.88 | MAPK14 (0.55) | MAPK14CCR8SMN1; SMN2 | |
| SCHEMBL6507357 | 0.86 | YAP1 (0.46) | MAPK14STSGPR119YAP1JAK2 | |
| SCHEMBL16669923 | 0.86 | MAPK14 (0.46) | MAPK14STSGPR119YAP1JAK2 | |
| SCHEMBL16670428 | 0.78 | YAP1 (0.53) | MAPK14STSGPR119YAP1JAK2 | |
| SCHEMBL26483782 | 0.74 | YAP1 (0.47) | STSGPR119YAP1JAK2JAK1 | |
| SCHEMBL3523774 | 0.74 | HCAR1 (0.47) | STSGPR119YAP1JAK2JAK1 | |
| SCHEMBL16669790 | 0.74 | HCAR1 (0.41) | STSGPR119KDM4EPKMHCAR1 | |
| SCHEMBL19970722 | 0.74 | GPR119 (0.53) | STSGPR119YAP1CCR8JAK2 | |
| SCHEMBL27369897 | 0.74 | GPR119 (0.44) | STSGPR119KDM4EPKMTHRB | |
| SCHEMBL4482872 | 0.73 | MAPK14 (0.52) | MAPK14STSGPR119YAP1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | MAPK14 333/4885STS 299/4885GPR119 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.